| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 7,209 | 7,183 |
| Net increase (decrease) in cash and cash equivalents | 1,318 | 2,586 |
| Cash and cash equivalents at beginning of period | 1,729 | - |
| Cash and cash equivalents at end of period | 3,047 | - |
Ernexa Therapeutics Inc. (ERNA)
Ernexa Therapeutics Inc. (ERNA)